According to the report analysis, ‘Global Circulating Tumor Cell Market Research Report – Forecast to 2023’ states that some of the major companies which are currently functioning in this sector more actively for attaining the highest share by overcoming the demand of the potential buyers includes Greiner Bio-One International GmbH, Ikonisys Inc., Thermo Fisher Scientific, SRI International, STEMCELL Technologies, Miltenyi Biotec, Menarini Silicon Biosystems, QIAGEN Hannover (QIAGEN), F. Hoffmann-La Roche Ltd, NanoString Technologies, Inc., Fluxion Biosciences, Inc., and GE Healthcare. Moreover, the key players are analyzing the market insights, structure along with a forecast of various segments of the global circulating tumor cells market for gaining the effective share across the globe. For instance, the National Center for Biotechnology Information (NCBI) stated that the projected cases of prostate cancer all over the India in the year 2015 were 28,079. Additionally, the Leukemia & Lymphoma Society estimated that around, 60,300 citizenry are anticipated to be diagnosed with leukemia in 2018. The effective growth in the population of cancer victims is concreting a way for the market growth of the circulating tumor cells.
The circulating tumor cells are the cells that have shed into the lymphatics and vasculature from a frequent tumor and are connected around the body with the blood circulation. Circulating tumor cells can be utilized as a blood biomarker for the initial diagnosis of carcinogenesis and cancer and support to monitor prostate cancers, monitor metastatic breast and colorectal. Meanwhile, the growth of circulating tumor cells market can be operated by the increasing frequency of rising research, cancer and development in the biotechnology and pharmaceutical industry with the rising geriatric citizenry. The increasing occurrence of cancer is operating the growth of the market, as circulating tumor cells find their applications and benefits in the diagnosis of cancer and accuracy management. The global market of circulating tumor cells is segmented differently which includes by application, technology, end-user and region. Therefore, with the wide segmentation in the recent trend the market has grown more effectively across the globe.
According to the National Health and Medical Research council, the Australian government spent over USD 174.6 million on cancer research and development. This rising research and development in the sector of healthcare are foremost to the growth of the circulating tumor cells market. Moreover, on the basis of region the market is spread across the globe which majorly includes Americas, Europe, Asia Pacific region, Middle East & Africa and rest of the world. Meanwhile, the global circulating tumor cells market was appreciated USD 9,393.1 million in 2017 and is anticipated to account a CAGR of 20.3% over the near future.
The key players are adopting the effective strategies and policies and doing detailed analysis of the value chain and supply chain of the global circulating tumor cells market for attaining the highest share across the globe. Therefore, in the coming years it is expected that the market of circulating tumor cells will grow more significantly across the globe more significantly over the decades.
To know more, click on the link below:
Ankur Gupta, Head Marketing & Communications